Los Angeles Capital Management LLC Has $405,000 Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Los Angeles Capital Management LLC boosted its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 138.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 201,439 shares of the company’s stock after buying an additional 116,853 shares during the period. Los Angeles Capital Management LLC’s holdings in RAPT Therapeutics were worth $405,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of RAPT. Vanguard Group Inc. grew its stake in RAPT Therapeutics by 21.2% during the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock valued at $22,386,000 after acquiring an additional 436,629 shares in the last quarter. Point72 Asset Management L.P. grew its stake in RAPT Therapeutics by 176,725.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after acquiring an additional 706,900 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in RAPT Therapeutics by 826.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock valued at $900,000 after acquiring an additional 263,372 shares in the last quarter. Acadian Asset Management LLC grew its stake in RAPT Therapeutics by 4,183.3% during the 2nd quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after acquiring an additional 456,275 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in RAPT Therapeutics during the 2nd quarter valued at about $108,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a research note on Monday, November 11th. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, November 12th. Finally, Wells Fargo & Company lowered their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, RAPT Therapeutics presently has an average rating of “Hold” and an average price target of $9.50.

RAPT Therapeutics Stock Down 13.7 %

Shares of RAPT Therapeutics stock opened at $1.11 on Monday. The stock has a market capitalization of $38.63 million, a P/E ratio of -0.40 and a beta of 0.33. The stock has a 50 day moving average price of $1.93 and a two-hundred day moving average price of $2.92. RAPT Therapeutics, Inc. has a 12-month low of $1.03 and a 12-month high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. Sell-side analysts anticipate that RAPT Therapeutics, Inc. will post -2.8 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.